Home / World Marketplace / Global Corporate Affairs / Archive by category Survey and Research (Page 64)

Archive by category Survey and Research

Io Therapeutics, Inc., Presented Today Results from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Treatment of Amyotrophic Lateral Sclerosis (ALS)

SPRING, Texas, July 16, 2024 (Korea Bizwire) – Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS). The presentation titled “The RXR Nuclear Receptor Agonist Compound IRX4204 is a [...]

Bedford Metals Identifies Key Uranium Markers at Close Lake Uranium Project

VANCOUVER, British Columbia, July 16, 2024 (Korea Bizwire) – Bedford Metals Corp. (TSX-V: BFM, FWB: O8D, ISIN: CA0762301012) (the “Company” or “Bedford”) is pleased to announce the results of its VNIR (Visible Near Field Infrared) and SWIR (Shortwave Infrared) satellite investigation at the Close Lake Uranium Project in the Athabasca Basin, Saskatchewan. An analysis conducted by Dr. [...]

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine

WASHINGTON, July 15, 2024 (Korea Bizwire) – Sabin Vaccine Institute launched a Phase 2 clinical trial for its vaccine against Sudan ebolavirus, with healthy volunteers receiving the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Uganda. There are currently no approved vaccines for this strain of ebolavirus, which saw an outbreak end just last year. [...]

New Report Highlights Global Trends and Advances in Chronic Lymphocytic Leukemia Research and Treatment

BOSTON, Jul. 11 (Korea Bizwire) — Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has today released a significant research report entitled Chronic Lymphocytic Leukemia (CLL) – Global Clinical Trial Landscape. This expert monthly report, provided by the [...]

FSH-free versus FSH-primed Infertility Treatment of Women with Polycystic Ovary Syndrome using Biphasic in Vitro Maturation: a Randomized Clinical Trial

AMSTERDAM, July 10, 2024 (Korea Bizwire) – This randomized, controlled trial was conducted at a tertiary IVF center, Ho Chi Minh City, Vietnam. Between January 2023 and June 2023, 120 women were randomized. Eligible women were aged 18–37 years with polycystic ovarian syndrome (PCOS). After providing written informed consent, participants were randomized (1:1) to undergo [...]

Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective Third Generation RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Prevention and Treatment of Normal Aging-related Neurodegeneration, Parkinson’s Disease, and Alzheimer’s Disease

SPRING, Texas, Jul. 9 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, orally [...]

Bedford Metals Completes Sheppard Lake Uranium Project Option Agreement

VANCOUVER, British Columbia, July 09, 2024 (Korea Bizwire) – Bedford Metals Corp. (TSX-V: BFM, FWB: O8D, ISIN: CA0762301012) (the “Company” or “Bedford”) is pleased to announce that following completion of a diligence review, it has entered into a definitive option agreement (the “Option Agreement”), dated July 8, 2024, with an arms-length vendor, pursuant to which it has [...]

Io Therapeutics, Inc., Announces Presentation of Data on Induction of Tumor Growth Inhibiting Anti-cancer Immune Responses in Multiple Types of Cancers by a IRX5010, a Novel Retinoic Acid Nuclear Receptor Agonist Compound

SPRING, Texas, Jul. 8 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done in breast, lung, colorectal, and prostate cancer models with the company’s newest anti-cancer compound IRX5010, an agonist of retinoic acid nuclear receptor gamma which was discovered in the company’s oncology drug program. The presentation titled “RAR Gamma Agonist Compounds [...]

At the Yacht Club de Monaco Alternative Fuels Take Center Stage

MONACO, July 05, 2024 (Korea Bizwire) – ‘Alternative fuels and advanced yachting technology’. It is the title of one of the conferences held at the Yacht Club de Monaco during the Monaco Energy Boat Challenge week, aiming to build the yachting sector of the future. Sharing the goal of the Monaco Capital of Advanced Yachting [...]

OSL Partners Led 88% of Trading in Hong Kong’s Spot Digital Asset ETFs

OSL partner issuers account for 93% & 70% of the Spot BTC & ETH ETFs turnover HONG KONG, July 05, 2024 (Korea Bizwire) – The Hong Kong ETF market has witnessed substantial growth from its launch in April 2024, marked by impressive trading volumes and expanding assets under management (AUM). The spot Bitcoin (BTC) ETF recorded [...]